Particularly, at day 72, freshly isolated CD8 T-cells from survivor mice exhibited effective recognition not only to PLK1122-pulsed targets but also towards C1498 tumour cells (Fig. S5C), suggesting that the sufficient endurance of PD-L1 blockade could potentiate the therapeutic effectiveness of PLK1122DC_TriVax to C1498 myeloid leukaemia. This evidence concerns the gene CD8A and myeloid leukemia.